#AACR: Merck spotlights pivotal Keytruda/chemo data, hoping to break down skepticism to its frontline lung cancer duo
CHICAGO — Merck wowed the immuno-oncology market early this year with the headline news that its pivotal KEYNOTE-189 study demonstrated a clear success for Keytruda combined with chemo in treating frontline lung cancer cases. And at AACR in Chicago today, its investigators spelled out the promising results — demonstrating that the combo reduced the risk of death by half with a hazard ratio of 0.49 — as Merck looks to hold back a wave of major league competitors as it carves out a bigger share of the blockbuster lung cancer market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.